Oral Semaglutide 25 mg Versus Orforglipron 36 mg in Obesity: A Population‐Adjusted Indirect Treatment Comparison
Authors' conclusion
In this ITC, oral semaglutide 25 mg was associated with greater body weight loss and fewer discontinuations due to any AEs and due to GI AEs compared with orforglipron 36 mg.
Study context
- Population
- Adults with overweight (BMI ≥ 27 kg/m² and ≥1 obesity-related complication) or obesity (BMI ≥ 30 kg/m²), without diabetes; data from OASIS 4 and ATTAIN-1
- Comparison
- Oral semaglutide 25 mg vs orforglipron 36 mg
- Outcome
- Percentage change from baseline in body weight
Methodological detailsanchored indirect treatment comparison, individual patient data from OASIS 4 and aggregate data from ATTAIN-1, adjusted for sex, body weight and normoglycaemic status
- Anchored indirect treatment comparison
- Individual patient data from OASIS 4 and aggregate data from ATTAIN-1
- Adjusted for sex, body weight and normoglycaemic status
Pooled result
As reported in the abstract
Oral semaglutide 25 mg vs Orforglipron 36 mgMD, %-points (95% CI)
Treatment-regimen estimand
−3.2(−5.9 to −0.4)
Efficacy estimand
−3.0(−5.8 to −0.3)
Safety
| Outcome | OR (95% CI) | |
|---|---|---|
| Treatment discontinuation due to AEsOrforglipron 36 mgvs Oral semaglutide 25 mgDue to any AE | 4.1 (1.3–13.0) | |
| Treatment discontinuation due to AEsOrforglipron 36 mgvs Oral semaglutide 25 mgDue to GI AEs | 13.9 (2.0–96.0) | |
| 0.050.21520Odds ratio (log scale) |
Original publication
Oral Semaglutide 25 mg Versus Orforglipron 36 mg in Obesity: A Population‐Adjusted Indirect Treatment Comparison. Diabetes Obes Metab. Published 1 June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →